Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHL033
MIFTS: 33

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Childhood Malignant Schwannoma

About this section

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 71
Pediatric Mpnst 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:7732
NCIt 50 C8094
UMLS 71 C0279987
Sources

Summaries for Childhood Malignant Schwannoma

About this section
MalaCards based summary : Childhood Malignant Schwannoma, also known as childhood neurofibrosarcoma, is related to mechanical ectropion and multifocal osteogenic sarcoma. An important gene associated with Childhood Malignant Schwannoma is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are cellular and homeostasis/metabolism

Sources

Related Diseases for Childhood Malignant Schwannoma

About this section

Diseases related to Childhood Malignant Schwannoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 mechanical ectropion 10.4 NFIC NF1
2 multifocal osteogenic sarcoma 10.4 TP53 SPP1
3 esophageal leukoplakia 10.4 TP53 CCND1
4 vulvar intraepithelial neoplasia 10.4 TP53 BIRC5
5 pancreatic foamy gland adenocarcinoma 10.3 TP53 CCND1
6 esophagus verrucous carcinoma 10.3 TP53 CCND1
7 spinal cord oligodendroglioma 10.3 TP53 NF1
8 pediatric angiosarcoma 10.3 TP53 TCHP
9 optic nerve neoplasm 10.3 NFIC NF1
10 breast hemangioma 10.3 TP53 TCHP
11 cervical carcinosarcoma 10.3 MYOG BIRC5
12 mammary analogue secretory carcinoma 10.3 TP53 CCND1
13 malignant triton tumor 10.3 NF1 MYOG
14 orbit embryonal rhabdomyosarcoma 10.3 NF1 MYOG
15 scrotum neoplasm 10.3 NFIC MYOG
16 bladder transitional cell papilloma 10.3 TP53 BIRC5
17 cerebellum cancer 10.3 TP53 NF1
18 undifferentiated embryonal sarcoma of the liver 10.3 TP53 MYOG
19 embryonal sarcoma 10.3 TP53 MYOG
20 neurofibrosarcoma 10.2 TP53 NFIC NF1
21 keratocystic odontogenic tumor 10.2 TP53 CCND1 BIRC5
22 plexiform neurofibroma 10.2 TP53 NFIC NF1
23 epithelioid malignant peripheral nerve sheath tumor 10.2 NF1 MYOG
24 breast sarcoma 10.2 TP53 MYOG
25 parameningeal embryonal rhabdomyosarcoma 10.2 TP53 MYOG
26 cystadenocarcinoma 10.2 TP53 SPP1 BIRC5
27 infratentorial cancer 10.2 TP53 NF1 CCND1
28 malignant pleural mesothelioma 10.2 TP53 SPP1 BIRC5
29 inflammatory myofibroblastic tumor 10.2 TP53 CCND1 BIRC5
30 clear cell basal cell carcinoma 10.2 TP53 MYOG
31 ectodermal dysplasia 1, hypohidrotic, x-linked 10.2 SPP1 NECTIN1 FN1
32 basal cell nevus syndrome 10.2 TP53 NF1 CCND1
33 retinal cancer 10.2 TP53 TCHP CCND1
34 conventional fibrosarcoma 10.2 TP53 FN1
35 cervical adenosarcoma 10.2 TP53 MYOG
36 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.1 SPP1 NECTIN1 FN1
37 leiomyosarcoma 10.1 TP53 NF1 MYOG
38 melanoma, cutaneous malignant 1 10.1 TP53 TCHP NF1 CCND1
39 urethral benign neoplasm 10.1 TP53 FUT4
40 thyroid gland follicular carcinoma 10.1 TP53 FN1 CCND1
41 cerebellar angioblastoma 10.1 TCHP EWSR1
42 synchronous bilateral breast carcinoma 10.1 TP53 CCND1
43 localized osteosarcoma 10.1 TP53 EWSR1
44 extracranial neuroblastoma 10.1 MYOG EWSR1
45 cervical neuroblastoma 10.1 MYOG EWSR1
46 central nervous system mesenchymal non-meningothelial tumor 10.1 MYOG EWSR1
47 colorectal adenocarcinoma 10.1 TP53 CCND1 AURKA
48 perforated corneal ulcer 10.0 PF4 FN1
49 iga glomerulonephritis 10.0 SPP1 PF4 FN1
50 uterus leiomyosarcoma 10.0 MYOG FUT4

Graphical network of the top 20 diseases related to Childhood Malignant Schwannoma:



Diseases related to Childhood Malignant Schwannoma
Sources

Symptoms & Phenotypes for Childhood Malignant Schwannoma

About this section

MGI Mouse Phenotypes related to Childhood Malignant Schwannoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 AURKA BIRC5 CCND1 FN1 FOXM1 FUT4
2 homeostasis/metabolism MP:0005376 10.21 BIRC5 CCND1 FN1 FOXM1 FUT4 MDK
3 cardiovascular system MP:0005385 10.16 AURKA CCND1 FN1 FOXM1 FUT4 MDK
4 mortality/aging MP:0010768 10.07 AURKA BIRC5 CCND1 FN1 FOXM1 MDK
5 craniofacial MP:0005382 10.01 CCND1 FN1 NECTIN1 NF1 NFIC SPP1
6 liver/biliary system MP:0005370 9.87 FN1 FOXM1 MDK NF1 SPP1 TIMP3
7 neoplasm MP:0002006 9.7 AURKA CCND1 FN1 FOXM1 NF1 SPP1
8 respiratory system MP:0005388 9.5 CCND1 FOXM1 MYOG NF1 SPP1 TIMP3
9 skeleton MP:0005390 9.28 CCND1 FN1 MYOG NECTIN1 NF1 NFIC
Sources

Drugs & Therapeutics for Childhood Malignant Schwannoma

About this section

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
3
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Liposomal doxorubicin Phase 3 31703
12 Immunosuppressive Agents Phase 3
13 Antibiotics, Antitubercular Phase 3
14 Antimitotic Agents Phase 3
15 Immunologic Factors Phase 3
16 Alkylating Agents Phase 3
17 Anti-Bacterial Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Antirheumatic Agents Phase 3
20
Isophosphamide mustard Phase 3 100427
21 Etoposide phosphate Phase 3
22 Tubulin Modulators Phase 3
23 Neurotransmitter Agents Phase 3
24 Gastrointestinal Agents Phase 3
25 Histamine Antagonists Phase 3
26
Histamine Phosphate Phase 3 51-74-1 65513
27 Anti-Allergic Agents Phase 3
28 Histamine H1 Antagonists Phase 3
29 Dermatologic Agents Phase 3
30
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
31
Lenograstim Approved, Investigational Phase 2 135968-09-1
32 Protein Kinase Inhibitors Phase 2
33 Imatinib Mesylate Phase 2 220127-57-1 123596
34
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
35 Anti-Inflammatory Agents Phase 1
36 Analgesics, Non-Narcotic Phase 1
37 Cyclooxygenase 2 Inhibitors Phase 1
38 Anti-Inflammatory Agents, Non-Steroidal Phase 1
39 Analgesics Phase 1
40 Cyclooxygenase Inhibitors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
5 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
6 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrexâ„¢ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
7 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Sources

Genetic Tests for Childhood Malignant Schwannoma

About this section
Sources

Anatomical Context for Childhood Malignant Schwannoma

About this section

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

40
Bone
Sources

Publications for Childhood Malignant Schwannoma

About this section

Articles related to Childhood Malignant Schwannoma:

# Title Authors PMID Year
1
Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. 61
31889416 2020
2
Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. 61
31241238 2019
3
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. 61
30883338 2019
4
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). 61
24303016 2013
Sources

Variations for Childhood Malignant Schwannoma

About this section
Sources

Expression for Childhood Malignant Schwannoma

About this section
Search GEO for disease gene expression data for Childhood Malignant Schwannoma.
Sources

Pathways for Childhood Malignant Schwannoma

About this section

Pathways related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.33 TP53 TIMP3 SPP1 PF4 NF1 MDK
2
Phospholipase-C Pathway 63
Show member pathways
 12.83 TP53 TIMP3 SPP1 MDK HDGF FN1
3
DNA Damage 4
12.3 TP53 FOXM1 CCND1 AURKA
4
Proteoglycans in cancer 36
12.05 TP53 TIMP3 FN1 CCND1
5
Integrated Breast Cancer Pathway 1
11.86 TP53 NF1 CCND1 AURKA
6
Glioblastoma Multiforme 63
11.76 TP53 NF1 CCND1
7
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.66 SPP1 MYOG FN1
8
Small cell lung cancer 36
11.63 TP53 FN1 CCND1
9
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.55 MYOG KCNIP4 CCND1
10
Hepatitis C and Hepatocellular Carcinoma 1
11.29 TP53 CCND1 BIRC5
11
FOXM1 transcription factor network 1
11.07 FOXM1 CCND1 BIRC5
12
Interleukin-4 and 13 signaling 65
10.98 TP53 FN1 CCND1 BIRC5
13
G-protein signaling_Rap2B regulation pathway 23
10.64 TIMP3 SPP1 PF4 MDK HDGF FN1
14
Aurora A signaling 1
10.62 TP53 BIRC5 AURKA
Sources

GO Terms for Childhood Malignant Schwannoma

About this section

Cellular components related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.02 TIMP3 PF4 MDK HDGF FN1
2 chromosome passenger complex GO:0032133 8.96 BIRC5 AURKA

Biological processes related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.63 TP53 MYOG FOXM1 CCND1 BIRC5 AURKA
2 response to organic substance GO:0010033 9.58 TIMP3 SPP1 CCND1
3 response to wounding GO:0009611 9.54 MDK FN1 AURKA
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 FOXM1
5 mitotic G1 DNA damage checkpoint GO:0031571 9.32 TP53 CCND1
6 negative regulation of neuroblast proliferation GO:0007406 9.26 TP53 NF1
7 regulation of cell cycle GO:0051726 9.26 TP53 FOXM1 CCND1 BIRC5
8 cytokine-mediated signaling pathway GO:0019221 9.02 TP53 PF4 FN1 CCND1 BIRC5

Molecular functions related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TP53 TIMP3 TCHP SPP1 PF4 NFIC
2 protease binding GO:0002020 9.43 TP53 TIMP3 FN1
3 chaperone binding GO:0051087 9.33 TP53 FN1 BIRC5
4 proximal promoter sequence-specific DNA binding GO:0000987 9.13 TP53 NFIC MYOG
5 heparin binding GO:0008201 8.92 PF4 MDK HDGF FN1
Sources

Sources for Childhood Malignant Schwannoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....